Navigation Links
Sanofi-aventis to Acquire TargeGen, Inc.
Date:6/30/2010

SAN DIEGO, June 30 /PRNewswire/ -- TargeGen, Inc., a privately held biotechnology company focused on the development of small molecule kinase inhibitors today announced that the Company has agreed to be acquired by sanofi-aventis (EURONEXT: SAN; NYSE: SNY). Under the agreement, the ultimate purchase price will depend on the achievement of certain future milestones events and will total $560M if such milestones are fully realized. The closing of the transaction is expected to occur in the 3rd quarter of 2010.

(Logo: http://photos.prnewswire.com/prnh/20030430/TARGEGENLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

Formed in 2001, TargeGen's most advanced drug candidate is TG101348, an internally discovered, oral, potent, and highly selective JAK2 kinase inhibitor being developed for the treatment of patients with myeloproliferative diseases including primary and secondary myelofibrosis (MF) and polycythemia vera (PV). There are currently no approved drugs to treat MF or PV. Preliminary data from a 59 patient trial involving the treatment of MF patients with TG101348 were presented at the American Society of Hematology (ASH) Conference in New Orleans in December 2009. Other pre-clinical data prese
'/>"/>

SOURCE TargeGen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ascenta Therapeutics Licenses Cancer Drug Candidates to sanofi-aventis
2. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
5. Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit
6. Sanofi-aventis Announces Second Quarter 2009 Results
7. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
10. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
11. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014   MSC , a ... safety, today announced the appointment of Mary Beth ... With 28 years of experience preparing companies for rapid ... as Executive Vice President of Corporate Development and Healthcare. ... improvement business , as well as corporate strategy and ...
(Date:8/27/2014)... 27, 2014 The Global and China ... on the current state of the Trifluoroacetic Acid industry ... basic overview of the industry, including definitions, applications and ... market analysis are provided with a focus on history, ... comparison between the international and Chinese situation is also ...
(Date:8/27/2014)... Aug. 27, 2014 Research and ... "Global Lactic Acid  (Biodegradable Polymer, Food & Beverage, ... Forecasts to 2019" report to their offering. ... acid with an asymmetrical carbon atom. The main ... polymer, food and beverage, personal care product, and ...
(Date:8/27/2014)... , Aug. 27, 2014  A novel biomarker ... help physicians better identify early-stage disease, when treatment ... according to a new study in The Journal ... (NYSE: DGX ) and other institutions ... protein outperformed conventional antibody-serum testing, including rheumatoid factor ...
Breaking Biology Technology:MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4
... TRIANGLE PARK, N.C., Aug. 27 NovaQuest ... Inc., a,clinical-stage biopharmaceutical company specializing in respiratory,disorders. ... placement of C$26 million,(US$25 million) in the ... by NovaQuest, the strategic partnering group,of Quintiles ...
... HONG KONG, Aug. 27 /Xinhua-PRNewswire-FirstCall/ -- China Technology,Development ... today,announced the appointment of Charlene Hua as the ... pursuant to a board,resolution passed on the same ... Committee of the Company. As Chief Financial ...
... BRIDGEWATER, N.J., Aug. 27 Sanofi-aventis,U.S. launched today ... chemotherapy,treatment Eloxatin(R) (oxaliplatin injection) for patients who have,adjuvant ... which is,expected to offer more convenience, efficiency and ... Previously, Eloxatin(R) had been,available in 50 mg and ...
Cached Biology Technology:NovaQuest Advances 'Virtual Development' Model With Strategic Investment in TOPIGEN Pharmaceuticals 2China Technology Announces New Chief Financial Officer 2China Technology Announces New Chief Financial Officer 3New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 3New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 4New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 5New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 6New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 7
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) ... the American College of Sports Medicine,s Conference on ... in Miami, Florida. These awards are meant ... and scientists from underrepresented groups into the mainstream ... the participation of young scientists at the American ...
(Date:8/28/2014)... new roads will be built worldwide by 2050. Many ... where they bring an influx of destructive loggers, hunters ... has created a ,global roadmap, for prioritising road building ... demands of development and environmental protection. , The map ... natural importance of ecosystems and a ,road-benefits, layer that ...
(Date:8/28/2014)... exports from Washington, Oregon, northern California, and Alaska totaled ... quarter of 2014, an increase of more than 10 ... U.S. Forest Service,s Pacific Northwest Research Station reported today. ... by 4 percent to 247 million board feet. , ... more than 5 percent to $390 million in the ...
Breaking Biology News(10 mins):Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3West coast log exports up, lumber exports down in second quarter of 2014 2
... This release is available in German . ... that Nadja Knoll found new proof in the nomad people of ... nutritionist from the Friedrich Schiller University Jena (Germany) analyzed the diet ... of the field study show that the Maasai are in a ...
... PROVIDENCE, R.I. [Brown University] In 1988, a mysterious invader ... likely arrived in ballast from commercial ships, and it found ... decades later, the crab, Hemigrapsus sanguineus , has expanded ... southward to North Carolina. Its numbers continue to expand, and ...
... ORLEANS, LA Broncus Technologies, Inc., a medical device ... diseases, announced today at the American Thoracic Society ... system version 2.1. The bronchoscopic navigation system is ... These highlight the clinical benefits of using the ...
Cached Biology News:Nomad people baffle with good health in spite of malnourishment 2Are invasives bad? Not always, say Brown researchers 2LungPoint system results presented at American Thoracic Society 2010 International Conference 2LungPoint system results presented at American Thoracic Society 2010 International Conference 3
... an automated hybridization system for the processing ... the hybridization and post hybridization washing of ... instrument can process up to 12 slides ... multi-protocol software, enabling the user to run ...
a1-Antitrypsin (human, alpha-1 AT)...
C1-inhibitor (C1-INH)...
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
Biology Products: